Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Kraken Zone Discovery Unlocks Significant Value (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Neurosense Therapeutics Ltd NRSN

Alternate Symbol(s):  NRSNW

Healthcare Biotechnology
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3... see more

Recent & Breaking News (NDAQ:NRSN)

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

PR Newswire December 4, 2025

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

PR Newswire November 24, 2025

NeuroSense to Host Investor Webinar on December 8, 2025

PR Newswire November 3, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

PR Newswire October 6, 2025

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

PR Newswire September 10, 2025

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

PR Newswire September 4, 2025

NeuroSense Provides Business Update and Progress for the First Half of 2025

PR Newswire August 1, 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

PR Newswire July 22, 2025

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

PR Newswire May 7, 2025

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

PR Newswire April 24, 2025

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

PR Newswire April 9, 2025

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

PR Newswire April 7, 2025

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

PR Newswire April 4, 2025

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

Business Wire March 20, 2025

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Business Wire March 17, 2025

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

PR Newswire January 6, 2025

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

PR Newswire December 23, 2024

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

PR Newswire December 18, 2024

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

PR Newswire December 11, 2024

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

PR Newswire December 4, 2024

Podcasts